Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 15;64(suppl_1):S24-S29.
doi: 10.1093/cid/ciw828.

Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group

Sarah B Doernberg  1 , Thomas P Lodise  2 , Joshua T Thaden  3 , Jose M Munita  4   5 , Sara E Cosgrove  6 , Cesar A Arias  7 , Helen W Boucher  8 , G Ralph Corey  3 , Franklin D Lowy  9 , Barbara Murray  4 , Loren G Miller  10 , Thomas L Holland  3   11 ; Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG)
Affiliations
Review

Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group

Sarah B Doernberg et al. Clin Infect Dis. .

Abstract

Antimicrobial resistance in gram-positive bacteria remains a challenge in infectious diseases. The mission of the Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG) is to advance knowledge in the prevention, management, and treatment of these challenging infections to improve patient outcomes. Our committee has prioritized projects involving methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to the scope of the medical threat posed by these pathogens. Approved ARLG projects involving gram-positive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomycin dosing on patient outcome in MRSA bloodstream infection (BSI); (2) defining, testing, and validating innovative assessments of patient outcomes for clinical trials of MRSA-BSI; (3) testing new strategies for "step-down" antibiotic therapy for MRSA-BSI; (4) management of staphylococcal BSIs in neonatal intensive care units; and (5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outcomes. This article outlines accomplishments, priorities, and challenges for research of infections caused by gram-positive organisms.

Keywords: Clostridium difficile infection.; Staphylococcus aureus; bloodstream infection; gram-positive bacteria; vancomycin-resistant enterococci.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Process to generate and implement a desirability of outcome ranking (DOOR) endpoint for Staphylococcus aureus bloodstream infection (SA-BSI) studies.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed 10 August 2016.
    1. Fowler VG, Jr, Boucher HW, Corey GR, et al. ; Staphylococcus aureus Endocarditis and Bacteremia Study Group Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653–65. - PubMed
    1. Holland TL, Arnold C, Fowler VG., Jr Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014; 312:1330–41. - PMC - PubMed
    1. McKinnell JA, Arias CA. Editorial commentary: linezolid vs daptomycin for vancomycin-resistant enterococci: the evidence gap between trials and clinical experience. Clin Infect Dis 2015; 61:879–82. - PMC - PubMed
    1. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825–34. - PMC - PubMed

MeSH terms

Substances